Miller, Todd W.

ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery

Estrogen and related hormone effectsAdvanced Breast Cancer Therapies

Cited by 346

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine

Breast Cancer Treatment StudiesProtein Tyrosine Phosphatases

Cited by 262

Statistical determination of synergy based on Bliss definition of drugs independence

Demidenko, E., & Miller, T. W. (2019) · PLOS ONE

Statistical Methods in Clinical TrialsComputational Drug Discovery Methods

Cited by 187

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE

Breast Cancer Treatment StudiesGene expression and cancer classification

Cited by 43

Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer

Traphagen, N. A., Schwartz, G. N., Tau, S., Roberts, A. M., Jiang, A., Hosford, S. R., Marotti, J. D., Goen, A. E., Romo, B. A., Johnson, A. L., et al. (2023) · Clinical Cancer Research

PARP inhibition in cancer therapyEstrogen and related hormone effects

Cited by 20